AnaptysBio Inc (NASDAQ:ANAB) price target set to $147.00 by Credit Suisse Group

Analyst Ratings For AnaptysBio Inc (NASDAQ:ANAB)

Story continues below

Today, Credit Suisse Group set its price target on AnaptysBio Inc (NASDAQ:ANAB) to $147.00 per share.

There are 8 Buy Ratings, 1 Hold Ratings, no Strong Buy Ratings, no Sell Ratings on the stock.

The current consensus rating on AnaptysBio Inc (NASDAQ:ANAB) is Buy with a consensus target price of $133.3333 per share, a potential 37.83% upside.

Some recent analyst ratings include

  • 9/18/2018-AnaptysBio Inc (NASDAQ:ANAB) had its Outperform rating reiterated by Wedbush with a $138.00 price target
  • 8/8/2018-AnaptysBio Inc (NASDAQ:ANAB) had its Hold rating reiterated by Royal Bank of Canada with a $84.00 price target
  • 8/7/2018-AnaptysBio Inc (NASDAQ:ANAB) had its Buy rating reiterated by Jefferies Financial Group with a $121.00 price target

    About AnaptysBio Inc (NASDAQ:ANAB)
    AnaptysBio, Inc., a clinical stage biotechnology company, engages in developing antibody product candidates focused on unmet medical needs in inflammation. The company's proprietary anti-inflammatory pipeline includes ANB020, an anti-interleukin-33 antibody for the treatment of moderate-to-severe adult atopic dermatitis, severe adult peanut allergy, and severe adult eosinophilic asthma; ANB019, an anti-interleukin-36R antibody for the treatment of rare inflammatory diseases, including generalized pustular psoriasis and palmo-plantar pustular psoriasis; and a portfolio of checkpoint receptor agonist antibodies for the treatment of certain autoimmune diseases. It also has an immuno-oncology partnership with TESARO, Inc. and TESARO Development, Inc. to develop and commercialize monospecific antibody product candidates targeting TIM-3 (TSR-022), LAG-3 (TSR-033), and PD-1 (TSR-042), as well as a bispecific antibody product candidate targeting PD-1 and LAG-3; and an inflammation partnership with Celgene Corporation to develop an anti-PD-1 agonist antibody (CC-90006) that is in Phase 1 trial. The company was formerly known as Anaptys Biosciences, Inc. and changed its name to AnaptysBio, Inc. in July 2006. AnaptysBio, Inc. was founded in 2005 and is based in San Diego, California.

    Recent Trading Activity for AnaptysBio Inc (NASDAQ:ANAB)
    Shares of AnaptysBio Inc closed the previous trading session at 96.21 −3.93 3.92% with 219453 shares trading hands.

    An ad to help with our costs